Biopharmaceutical company AbbVie recently unveiled the results from its Surveyor studies of ABT-493, the company's investigational hepatitis C virus regimen. The study showed that ABT-493 had high rates of sustained virological responses 12 weeks after patients discontinued treatment. Patients used for the study were non-cirrhotic and had active HCV infections.
"These results are encouraging and contribute to scientific knowledge about the potential for pan-genotypic options for treating chronic hepatitis C," Dr. Fred Poordad, vice president of Academic and Clinical Affairs at The Texas Liver Institute in San Antonio, said. "These data mark another important step in the continued research to help address the unmet needs of patients and the medical community."
Abbvie is conducting Surveyor-I and Surveyor-II trials, continuing Phase 2 clinical studies that will assess ABT-493 and ABT-530's safety and effectiveness.
"The Surveyor trials offer important new information about the potential to treat patients with chronic hepatitis C across multiple genotypes with our two direct-acting antiviral investigational regimen," Dr. Michael Severino, chief scientific officer of AbbVie, said. "AbbVie's ongoing hepatitis C research program demonstrates our commitment to make a remarkable impact on the lives of HCV patients."
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. It was formed in 2013 following separation from Abbott Labs.
